These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 7955452

  • 1. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism.
    Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC.
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):421-4. PubMed ID: 7955452
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
    Földes J, Tarján G, Szathmari M, Varga F, Krasznai I, Horvath C.
    Clin Endocrinol (Oxf); 1993 Nov; 39(5):521-7. PubMed ID: 8252739
    [Abstract] [Full Text] [Related]

  • 3. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.
    Pantazi H, Papapetrou PD.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1099-106. PubMed ID: 10720046
    [Abstract] [Full Text] [Related]

  • 4. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women.
    Gürlek A, Gedik O.
    Thyroid; 1999 Jun; 9(6):539-43. PubMed ID: 10411115
    [Abstract] [Full Text] [Related]

  • 5. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY, Weetman AP, Eastell R.
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
    [Abstract] [Full Text] [Related]

  • 6. Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole.
    Lupoli G, Nuzzo V, Di Carlo C, Affinito P, Vollery M, Vitale G, Cascone E, Arlotta F, Nappi C.
    Gynecol Endocrinol; 1996 Oct; 10(5):343-8. PubMed ID: 8915664
    [Abstract] [Full Text] [Related]

  • 7. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
    De Rosa G, Testa A, Giacomini D, Carrozza C, Astazi P, Caradonna P.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
    [Abstract] [Full Text] [Related]

  • 8. Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism.
    Ross DS, Ardisson LJ, Nussbaum SR, Meskell MJ.
    J Clin Endocrinol Metab; 1991 Feb; 72(2):507-9. PubMed ID: 1991818
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
    Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H.
    Clin Endocrinol (Oxf); 1992 May; 36(5):511-7. PubMed ID: 1617803
    [Abstract] [Full Text] [Related]

  • 11. Thyroid hormone treatment aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women.
    Knudsen N, Faber J, Sierbaek-Nielsen A, Vadstrup S, Sørensen HA, Hegedüs L.
    J Intern Med; 1998 Feb; 243(2):149-54. PubMed ID: 9566644
    [Abstract] [Full Text] [Related]

  • 12. Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH.
    Gam AN, Jensen GF, Hasselstrøm K, Olsen M, Nielsen KS.
    J Endocrinol Invest; 1991 Jun; 14(6):451-5. PubMed ID: 1774441
    [Abstract] [Full Text] [Related]

  • 13. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism.
    Faber J, Wiinberg N, Schifter S, Mehlsen J.
    Eur J Endocrinol; 2001 Oct; 145(4):391-6. PubMed ID: 11580994
    [Abstract] [Full Text] [Related]

  • 14. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
    Appetecchia M.
    Horm Res; 2005 Oct; 64(6):293-8. PubMed ID: 16269872
    [Abstract] [Full Text] [Related]

  • 15. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities.
    Sgarbi JA, Villaça FG, Garbeline B, Villar HE, Romaldini JH.
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1672-7. PubMed ID: 12679455
    [Abstract] [Full Text] [Related]

  • 16. Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma.
    De Menis E, Da Rin G, Roiter I, Legovini P, Foscolo G, Conte N.
    Horm Res; 1992 Apr; 37(6):217-20. PubMed ID: 1292974
    [Abstract] [Full Text] [Related]

  • 17. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
    Kung AW, Lorentz T, Tam SC.
    Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
    [Abstract] [Full Text] [Related]

  • 18. Bone metabolism in premenopausal women with nontoxic goiter and reduced serum thyrotropin levels.
    Faber J, Overgaard K, Jarløv AE, Christiansen C.
    Thyroidology; 1994 Apr; 6(1):27-32. PubMed ID: 7536445
    [Abstract] [Full Text] [Related]

  • 19. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.
    Faber J, Jensen IW, Petersen L, Nygaard B, Hegedüs L, Siersbaek-Nielsen K.
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):285-90. PubMed ID: 9578817
    [Abstract] [Full Text] [Related]

  • 20. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial.
    Benvenga S, Ruggeri RM, Russo A, Lapa D, Campenni A, Trimarchi F.
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3579-94. PubMed ID: 11502782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.